Valerius Biopharma AG is a biopharmaceutical company that has been founded to provide interchangeable treatment options for high-priced biologics, by developing specialty biosimilars including but not limited to orphan drug biosimilars. Our interdisciplinary team of experts combines decades of experience gained in the biotechnology and biosimilar industry. Excellent process science, deep knowledge and understanding of proteins with their underlying complexity, as well as profound clinical and regulatory expertise, are key factors of our success.
The product pipelines comprises four products currently in preclinical development stages and include monoclonal antibodies, enzymes and fusion proteins covering different therapeutic areas such as oncology, inflammation, ophthalmology and respiratory. The development of our future pipeline candidates is planned to commence in 2022.
The company is driven by a team with proven track-records in biopharmaceutical / biosimilar development and finance.
Company Details
- Employees
- 5
- Founded
- -
- Address
- Stänzlergasse 4, Basel,ch- 4051,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- valeriusbio.com
- Keywords
- PROGEN.
- HQ
- Basel, CH-
Valerius Biopharma Ag Questions
Valerius Biopharma Ag's website is valeriusbio.com
Valerius Biopharma Ag's LinkedIn profile is https://ch.linkedin.com/company/valeriusbio
Valerius Biopharma Ag has
5 employees.
View email and phone details for 5
employees at Valerius Biopharma Ag.
Valerius Biopharma Ag's industry is
Biotechnology Research
Valerius Biopharma Ag's top competitors are
Stratpharma,
Rhizen Pharmaceuticals Ag,
Basilea Pharmaceutica,
Yumab Gmbh,
Versameb Ag,
Corat Therapeutics Gmbh,
Progen,
Inscreenex Gmbh,
Avocet Bio Gmbh,
Abcalis Gmbh.
Valerius Biopharma Ag's categories are Biotechnology Research
Valerius Biopharma Ag's founding year is 2017
